• Vaccine Name: Double Inactivated whole SARS-CoV vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: Inactivated or "killed" vaccine
• Status: Licensed
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: whole virus (Tseng et al., 2012)
• Immunization Route: Intramuscular injection (i.m.)
• Description: Inactivated whole virus by formalin and Ultraviolet radiation, hence Double Inactivated (DI) Vaccine (Tseng et al., 2012)

Mouse Response

• Host Strain: Balb/c and C57BL/6 (Tseng et al., 2012)
• Host age: 6-8 weeks (Tseng et al., 2012)
• Host gender: Female (Tseng et al., 2012)
• Vaccination Protocol: Each mouse received 100 µl injection of each vaccine intramuscularly on days 0 and 28. The injection was done at 1 µg, 0.5 µg, 0.25 µg, 0.125 µg of the vaccine (Tseng et al., 2012)
• Immune Response: Increased titer of neutralizing antibodies and reduced viral titer (Tseng et al., 2012)
• Side Effects: Eosinophil infiltration in the lung lesions after challenge, type-2 hypersensitivity reaction (Tseng et al., 2012)
• Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 106TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
• Efficacy: protected (Tseng et al., 2012)